This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-3839v1 69/12/5073    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Moses, S. A. Articles by Meuillet, E. J. Search for Related Content PubMed PubMed Citation Articles by Moses, S. A. Articles by Meuillet, E. J.

In vitro and In vivo Activity of Novel Small-Molecule Inhibitors Targeting the Pleckstrin Homology Domain of Protein Kinase B/AKT

Departments of ¹ Molecular and Cellular Biology, ² Chemistry, and ³ Nutritional Sciences, The University of Arizona, Tucson, Arizona; ⁴ Department of Experimental Therapeutics, University of Texas, M. D. Anderson Cancer Center, Houston, Texas; and ⁵ OpenEye Scientific Software, Inc., Santa Fe, New Mexico

Requests for reprints: Emmanuelle J. Meuillet, Department of Nutritional Sciences, The University of Arizona, P. O. Box 210038, Tucson, AZ 85721-0038. Phone: 520-626-5794; Fax: 520-621-9446; E-mail: emeuillet{at}azcc.arizona.edu.

Key Words: AKT • pleckstrin homology domain • scid • in silico screen • pancreatic cancer

The phosphatidylinositol 3-kinase/AKT signaling pathway plays a critical role in activating survival and antiapoptotic pathways within cancer cells. Several studies have shown that this pathway is constitutively activated in many different cancer types. The goal of this study was to discover novel compounds that bind to the pleckstrin homology (PH) domain of AKT, thereby inhibiting AKT activation. Using proprietary docking software, 22 potential PH domain inhibitors were identified. Surface plasmon resonance spectroscopy was used to measure the binding of the compounds to the expressed PH domain of AKT followed by an in vitro activity screen in Panc-1 and MiaPaCa-2 pancreatic cancer cell lines. We identified a novel chemical scaffold in several of the compounds that binds selectively to the PH domain of AKT, inducing a decrease in AKT activation and causing apoptosis at low micromolar concentrations. Structural modifications of the scaffold led to compounds with enhanced inhibitory activity in cells. One compound, 4-dodecyl-N-(1,3,4-thiadiazol-2-yl)benzenesulfonamide, inhibited AKT and its downstream targets in cells as well as in pancreatic cancer cell xenografts in immunocompromised mice; it also exhibited good antitumor activity. In summary, a pharmacophore for PH domain inhibitors targeting AKT function was developed. Computer-aided modeling, synthesis, and testing produced novel AKT PH domain inhibitors that exhibit promising preclinical properties. [Cancer Res 2009;69(12):5073–81]